Antimicrobial Susceptibility Among Bacterial Isolates from ICU and Non-ICU Settings and Different Age Groups: Results from the Tigecycline Evaluation and Surveillance Trial in North America

References

• Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52: 113–122.
   PubMed Web of Science ®Google Scholar
• The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococ-cus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002; 23: 106–108.
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fish-man NO. Association between fluoroquinolone resistance and mortality in Escherichia coil and Klebsiella pneumoniae infec-tions: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005; 41: 923–929.
   PubMed Web of Science ®Google Scholar
• Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resis-tant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136: 834–844.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Moet GJ, Jones RN. Occurrence and an-timicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY antimicrobial surveillance program (1997-2002). Diagn Microbiol Infect Dis 2004; 50: 59–69.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standard for antimicrobial susceptibility testing, document M100-S16. 2006. Clinical and Laboratory Standards Institute, Wayne, PA.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, document M7-A6. 2003. National Com-mittee for Clinical Laboratory Standards, Wayne, PA.
   Google Scholar
• Wyeth Pharmaceuticals. Tygacil Product Insert. 2005. Wyeth Pharmaceuticals, Philadelphia, PA. [Online.] http://www.wyeth.com/hcp/tygacil. Accessed 2nd May 2008.
   Google Scholar
• Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5: 2 http://www.ann-clinmicrob.com/content/5/1/2.
   Google Scholar
• Diekema DJ, Pfaller MA, Jones RN. Age-related trends in pathogen frequency and antimicrobial susceptibility of blood-stream isolates in North America: SENTRY Antimicrobial Sur-veillance Program, 1997-2000. Int J Antimicrob Agents 2002; 20: 412–418.
   PubMed Web of Science ®Google Scholar
• Kirby JT, Fritsche TR, Jones RN. Influence of patient age on the frequency of occurrence and antimicrobial resistance pat-terns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). Diagn Microbiol Infect Dis 2006; 56: 75–82.
   PubMed Web of Science ®Google Scholar
• Tillotson GS, Draghi DC, Sahm DF, Tomfohrde KM, del Fabro T, Critchley IA. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study. J Antimicrob Chemother 2008; 62: 109–115.
   PubMed Web of Science ®Google Scholar
• Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial sus-ceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new gly-cylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50: 3479–3484.
   PubMed Web of Science ®Google Scholar
• Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro ac-tivity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-struc-ture infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41: S315–S332.
   PubMed Web of Science ®Google Scholar
• Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis 2008; 60: 421–427.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Decorby M, Nichol KA, Wierzbowski A, Baudnj PJ, Karlowsky JA et al. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis 2008; 62: 67–80.
   Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wen-zel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nation-wide surveillance study. Clin Infect Dis 2004; 39: 309–317.
   PubMed Web of Science ®Google Scholar
• Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resis-tant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179.
   PubMed Web of Science ®Google Scholar
• Swoboda S, Fritz S, Martignoni ME, Feldhues RA, Hoppe-Tichy T, Suchler MW, et al. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during ther-apy: a case report. J Antimicrob Chemother 2005; 56: 787–789.
   PubMed Web of Science ®Google Scholar
• Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H. Rapid emergence of resistance to linezolid during linezolid ther- apy of an Enterococcus faecium infection. Antimicrob Agents Chemother 2006; 50: 4217–4219.
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Forward KR, Litiares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acineto-bacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epi-demiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001; 32(Suppl 2): 104–113.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial suscepti-bility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1681–1688.
   PubMed Web of Science ®Google Scholar
• Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14 www.ann-clinmicrob.com/con-tent/3/1/14.
   Google Scholar
• Halstead DC, Abid J, Dowzicky MJ. Antimicrobial sus-ceptibility among Acinetobacter calcoaceticus-baumannii com-plex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007; 55: 49–57.
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream in-fection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52: 181–186.
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (includ-ing carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62: 45–
   PubMed Web of Science ®Google Scholar
• Winokur PL, Canton R, Casellas JM, Legakis N. Varia-tions in the prevalence of strains expressing an extended-spec-trum13-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin In-fect Dis 2001; 32 (Suppl 2): S94–S103.
   PubMedGoogle Scholar
• Paterson DL, Bonomo RA. Extended-spectrum I3-lacta-mases: a clinical update. Clin Microbiol Rev 2005; 18: 657–686.
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 2005; 52: 209–213.
   PubMed Web of Science ®Google Scholar